Outlook Therapeutics, Inc. (OTLK)
0.4882
-0.01
(-2.36%)
USD |
NASDAQ |
Oct 16, 16:00
0.4918
0.00 (0.00%)
After-Hours: 20:00
Outlook Therapeutics EPS Diluted (Quarterly) : -0.1486 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1486 |
| March 31, 2026 | -0.0544 |
| December 31, 2025 | -0.383 |
| June 30, 2025 | -0.5453 |
| March 31, 2025 | -1.502 |
| December 31, 2024 | 0.7171 |
| September 30, 2024 | 0.2381 |
| June 30, 2024 | -0.885 |
| March 31, 2024 | -8.009 |
| December 31, 2023 | -0.859 |
| September 30, 2023 | -0.9984 |
| June 30, 2023 | -1.610 |
| March 31, 2023 | -0.5186 |
| December 31, 2022 | -1.641 |
| September 30, 2022 | -1.262 |
| June 30, 2022 | -1.591 |
| March 31, 2022 | -1.799 |
| December 31, 2021 | -1.537 |
| September 30, 2021 | -1.519 |
| June 30, 2021 | -1.448 |
| March 31, 2021 | -1.739 |
| December 31, 2020 | -2.375 |
| Date | Value |
|---|---|
| September 30, 2020 | -1.560 |
| June 30, 2020 | -0.6644 |
| March 31, 2020 | -7.291 |
| December 31, 2019 | -12.36 |
| September 30, 2019 | -0.3586 |
| June 30, 2019 | -3.998 |
| March 31, 2019 | -19.59 |
| December 31, 2018 | -20.10 |
| September 30, 2018 | -28.03 |
| June 30, 2018 | -41.60 |
| March 31, 2018 | -54.40 |
| December 31, 2017 | -113.60 |
| September 30, 2017 | -48.48 |
| June 30, 2017 | -35.20 |
| March 31, 2017 | -60.80 |
| December 31, 2016 | -131.20 |
| September 30, 2016 | -74.34 |
| June 30, 2016 | -256.00 |
| March 31, 2016 | -32.09 |
| December 31, 2015 | -120.31 |
| December 31, 2014 | -48.72 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Valion Bio, Inc. | -52.54 |
| Agenus, Inc. | -0.0146 |
| Amgen, Inc. | 4.366 |
| Anika Therapeutics, Inc. | 0.2412 |
| BioCryst Pharmaceuticals, Inc. | 0.2957 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -20.32M |
| Revenue (Quarterly) | 0.0087M |
| Total Expenses (Quarterly) | 20.33M |
| Enterprise Value | 98.53M |
| Gross Profit Margin (Quarterly) | -254.0% |
| Profit Margin (Quarterly) | -233.6K% |
| Earnings Yield | -231.7% |
| Normalized Earnings Yield | -199.18 |